Eli Lilly, compounders partly to blame for Novo CEO’s ouster

Novo Nordisk (NVO) (OTCPK:NONOF) appears to have forced its CEO, Lars Fruergaard Jørgensen, to resign as the Danish pharma giant grapples with the rising dominance of its U.S. rival, Eli Lilly (NYSE:LLY), and makers of